Paraoxonase-1 55/192 genotypes in schizophrenic patients and their relatives in Turkish population

Psychiatric Genetics

Volumn 18, Issue 6, 2008, Pages 289-294

  Kucukali, Cem Ismail ^a   Aydin, Makbule ^b   Ozkok, Elif ^b   Orhan, Nurcan ^b   Cakir, Ulku ^c   Kilic, Gamze ^f   Ozbek, Zeynep ^d   Ince, Nurhan ^e   Kara, Ihsan ^b  

^a Istanbul Erenkoy Psychiatric and Neurological Disorders Hospital   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c VAKIF GUREBA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d Eyup State Hospital   (Turkey)

^e ISTANBUL UNIVERSITY   (Turkey)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Oxidative stress; Paraoxonase activity; Paraoxonase polymorphism; Relative; Schizophrenia

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; GENOMIC DNA; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; TURKEY (REPUBLIC);

ADULT; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; TURKEY;

EID: 57149135486     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/YPG.0b013e3283060f94     Document Type: Article

References (41)

1. Adkins S, Gan KN, Mody M, La Du BN (1993). Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for respective A or B alloenzymes. Am J Hum Genet 52:598-608.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental disorder. 4th ed. Washington DC: American Psychiatric Association, American Psychiatric Press.
3. Andreasen NC (1990). Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry 24:73-88.
4. Austine J (2005). An update and review. J Genetic Counsel 14:505.
5. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M (1998). Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Tromb Vasc Biol 18:1617-1624.
6. Aviram A, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. (1999). Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26:892-904.
7. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE (2001). Effect of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68:1428-1436.
8. Chouinard G, Ross-Chouinard A, Annable L, Jones B (1980). The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 7:233.
9. Cui K, Luo X, Xu K, Ven Murthy MR (2004). Role of oxidative stress in neurodegeneration: recent developments in assay methods for oxidative stress and nutraceutical antioxidants. Prog Neuropsychopharmacol Biol Psychiatry 28:771-799.
10. Endicott J, Spitzer RL (1978). A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35:837-862.
11. Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG (1989). Spectrophotometric assay for enzymatic hydrolysis of the active metabolites of chloropyrites and parathion by plasma paraoxonase/atylesterase. Anal Biochemistry 180:242-247.
12. Gutteridge JM, Halliwell B (2000). Free radicals and antioxidants in the year. A historical look to the future. Ann N Y Acad Sci 899:136-147.
13. Halliwell B (2001). Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18:685-716.
14. Hedrick CC, Hassan K, Hough GP, Yoo JH, Simzar S, Quinto CR, et al. (2000). Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler Thromb Vasc Biol 20:1946-1952.
15. Hoffer A, Osmond H, Smythies J (1954). Schizophrenia: a new approach. II. Results of year's research. J Ment Sci 100:29-45.
16. Humbert R, Adler DA, Disteche CM, Hasset C, Omieecinki CJ, Furlong CE (1993). The molecular basis of the human serum paraoxonase activity polymorphism. Nate Genet 3:73-76.
17. James RW, Leviev I, Righetti A (2000). Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101:2252-2257.
18. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE (2000). Paraoxonase (PON1) phenotype is a better predictor of vascular disease than PON1192 or PON155 genotype. Arterioscler Thromb Vasc Biol 20:2441-2447.
19. Keller JN, Hanni KB, Markesbery WR (1999). Oxidized low-density lipoprotein induces neuronal death: implications for calcium, reactive oxygen species, and caspases. J Neurochem 72:2601-2609.
20. Mackness MI, Arrol S, Durrington PN (1991). Paraoxonase prevents accumulation of lipid peroxide in low-density lipoprotein. FEBS Lett 286: 152-154.
21. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1998a). Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high-density lipoprotein against low-density lipoprotein oxidative modification. FEBS Lett 423:57-60.
22. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, et al. (1998b). Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139:341-349.
23. Magaro PA, Abrams L, Cantrell P (1981). The Maine Scale of paranoid and nonparanoid schizophrenia: reliability and validity. J Consul Clin Psychol 49:438-447.
24. Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, Mahadik JS (1998). Elevated plasma lipid peroxides at the onset of non-affective psychosis. Biol Psychiatry 43:674-679.
25. Mahadik SP, Pillai A, Joshi S, Foster A (2006). Prevention of oxidative stress mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry 18:119-131.
26. Matsumoto C, Ohmori O, Hori H, Shinkai T, Nakamura J (2002). Analysis of association between the Gln192Arg polymorphism of the paraoxonase gene and schizophrenia in humans. Neurosci Lett 321:165-168.
27. Miller SA, Dykes DD, Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
28. Nishio E, Watanabe Y (1997). Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 236:289-293.
29. Olanow CW (1993). A radical hypothesis for neurodegeneration. Trends Neurosci 16:439-444.
30. Overal JE, Gorhan DR (1962). The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
31. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN (1996). The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498-507.
32. Rafalowska U, Liu GJ, Floyd RA (1989). Peroxidation induced changes in synaptosomal transport of dopamine and gamma-aminobutyric acid. Free Radic Biol Med 6:465-492.
33. Reiter RJ (1995). Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J 9:526-533.
34. Sakai T, Matsuura B, Onji M (1998). Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus. Intern Med 37: 581-584.
35. Schwartz RD, Skolnick P, Paul SM (1988). Regulation of gamma-aminobutyric acid/barbiturate receptor-gated chloride ion flux in brain vesicles by phospholipase A2: possible role of oxygen radicals. J Neurochem 50: 565-571.
36. Sirota P, Gavrieli R, Wolach B (2003). Overproduction of neutrophil radical oxygen species correlates with negative symptoms in shizophrenic patients: parallel studies on neutrophil chemotaxis, superoxide production ana bactericidal activity. Psychiatry Res 121:123-132.
37. Tomas M, Senti M, Garcia-Faria F, Vila J, Torrents A, Covas M, Marrugat J (2000). Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 20:2113-2119.
38. Tsuang MT, Bar JL, Stone WS, Faraone SV (2004). Gene-environment interactions in mental disorders. World Psychiatry. 3:73-83.
39. Van der Gaag MS, van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, Hendricks HF (1999). Dairy moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle aged men. Atherosclerosis 147:405-410.
40. Van Lenten BJ, Wagner AC, Navab M, Fogelman AM (2001). Oxidized phospholipids induce changes in hepatic paraoxonase and apoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 276:1923-1929.
41. Yao JK, Reddy RD, van Kammen DP (2001). Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15:287-310.